Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal

SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization

Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion

Medanta expanded its bed capacity by 20% during the year

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore

Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

Merck posts mixed Q1 2026 results as blockbuster drugs drive growth

But acquisition charges drag earnings into loss

Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push

The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA

Cipla’s generic Ventolin HFA secures USFDA approval

Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

FDA clears Travere’s FILSPARI for expanded use in rare kidney disease